Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.

Abstract

Plaque psoriasis is the commonest form of psoriasis affecting about 85% of those patients with the condition. Risankizumab was developed as a high-affinity humanized monoclonal antibody specific for the p19 subunit of interleukin-23 (IL-23p19). Clinical trials demonstrated that risankizumab was very effective in patients with moderate to severe plaque psoriasis causing total clearing of the condition as evidenced by Psoriasis Scalp Severity Index (PSSI100) and static Physician's Global Assessment (sPGA) of 0 in more than 50% of patients after 52 weeks of treatment. Risankizumab has been approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy as a dose of 150 mg administered by subcutaneous injection at week 0, week 4 and every 12 weeks thereafter.

• Authors: D M Paton
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 55 Issue 10 Pg. 605-613 (Oct 2019) ISSN: 1699-3993 [Print] Spain
• PMID: 31720558 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2019 Clarivate Analytics.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Interleukin-23 Subunit p19
• risankizumab

Topics

• Antibodies, Monoclonal (pharmacology)
• Antibodies, Monoclonal, Humanized (pharmacology)
• Drug Approval
• Humans
• Interleukin-23 Subunit p19 (antagonists & inhibitors, immunology)
• Psoriasis (therapy)
• Treatment Outcome
• United States
• United States Food and Drug Administration